The Company estimates that: Record ZTlido gross sales for October 2023 were in the range of $14.5 million to $15.5 million with record year-to-date gross sales through October 2023 in the range of $110.0 million to $120.0 million, compared to $74.8 million for year-to-date through October 2022, representing growth in the range of 47% to 60%. Full year gross sales for ZTlido in 2022 were $96.0 million. ZTlido net sales for October 2023 were in the range of $4.0 million to $5.0 million with year-to-date net sales through October 2023 in the range of $35.0 million to $40.0 million, compared to $30.4 million for year-to-date through October 2022, representing growth in the range of 15% to 32%. Full year net sales for ZTlido in 2022 were $38.0 million. Total product gross sales for October 2023 were in the range of $15.5 million to $16.5 million with year-to-date total product gross sales through October 2023 in the range of $115.0 million to $125.0 million, compared to $74.8 million for year-to-date through October 2022, representing growth in the range of 54% to 67%. Total product net sales for October 2023 were in the range of $4.0 million to $5.0 million with year-to-date total product net sales through October 2023 in the range of $35.0 million to $40.0 million, compared to $30.4 million for year-to-date October 2022, representing growth in the range of 15% to 32%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SCLX:
- Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)
- Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders
- Scilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended October 2023, And Year-To-Date Through October 31, 2023, Based On Currently Available Information
- UPDATE — Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure
- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure